Lab+Life Scientist Nov 2014

Page 22

what’s new

Plano-convex lenses Edmund Optics introduces TechSpec Calcium Fluoride Plano-Convex (PCX) Lenses. The lenses are suitable for use in demanding applications that require good performance from the ultraviolet (UV) through the mid-wave infrared (MWIR) spectra. Featuring a low index of refraction, high laser damage threshold and low axial and radial-stress birefringence, the lenses are suitable for use with Excimer lasers or for integration into IR systems. The lenses, manufactured using a vacuum-grade UV substrate, offer greater than 90% transmission

NGS workstation for LC-MSMS IVD kit

from 193 nm to 7 µm. Calcium fluoride is characterised by its low solubil-

Tecan and RECIPE Chemicals and Instruments have announced a co-marketing

ity and is said to offer better hardness in comparison

agreement for the automation of LC-MSMS IVD kits.

to other fluoride-based substrates. This makes the

Tecan’s flexible Freedom EVO platform offers walkaway automation of the

lenses able to withstand harsh environments and

RECIPE ClinMass LC-MSMS Complete Kits for the analysis of vitamin D2/D3

exposure to the elements. They are available in

and immunosuppressants. The automated process is claimed to eliminate

12.5, 25 and 50 mm diameters.

the potential for manual handling errors and increase the speed of sample

The uncoated lenses feature a positive focal length,

preparation three-fold compared to manual protocols, improving turnaround

ranging from 18 to 150 mm, and have one flat and

times while enhancing reproducibility, traceability and sample security.

one convex surface. They are RoHS compliant.

Tecan Australia

Edmund Optics Singapore Pte Ltd

www.tecan.com.au

www.edmundoptics.com

Pre-packed columns WR Grace & Co has introduced ProVance prepacked Protein A columns for purification of biologic drugs, specifically monoclonal antibodies (mAbs). The columns bring together Protein A resin and a convenient prepacked column format designed specifically for facilities sites that have moved to single-use manufacturing methodologies. The portfolio of disposable columns comes prepacked with a silicabased Protein A resin claimed to have a higher capacity than alternative technology used for mAb purification. Biopharmaceutical users are said to have confirmed 40 to 60% total operational cost reduction with the columns by eliminating timeconsuming cleaning and packing steps and achieving increased efficiency. The prepacked disposable columns further improve biopharmaceutical productivity by lowering the risk of contamination and accelerating time to market. Grace Davison Discovery Sciences www.discoverysciences.com/au

22 | LAB+LIFE SCIENTIST - November 2014

www.LabOnline.com.au | www.LifeScientist.com.au